{"id":"lucentis-every-4-weeks","safety":{"commonSideEffects":[{"rate":"25–30%","effect":"Conjunctival hemorrhage"},{"rate":"5–10%","effect":"Eye pain"},{"rate":"5–10%","effect":"Floaters"},{"rate":"5–10%","effect":"Intraocular pressure elevation"},{"rate":"0.05–0.1%","effect":"Endophthalmitis"},{"rate":"<1%","effect":"Retinal detachment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By blocking VEGF-A signaling, it prevents endothelial cell proliferation and reduces retinal edema, thereby stabilizing or improving vision in conditions characterized by abnormal retinal vasculature.","oneSentence":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:38.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT06176352","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2024-03-06","conditions":"Choroidal Neovascularization Secondary to Pathologic Myopia","enrollment":280},{"nctId":"NCT03683251","phase":"PHASE3","title":"Extension Study for the Port Delivery System With Ranibizumab (Portal)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1000},{"nctId":"NCT04503551","phase":"PHASE3","title":"A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-10","conditions":"Diabetic Retinopathy","enrollment":174},{"nctId":"NCT07389577","phase":"PHASE3","title":"A Study to Compare JL14002 to Lucentis® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Jecho Biopharmaceuticals Co., Ltd.","startDate":"2022-03-01","conditions":"Wet Age-related Macular Degeneration","enrollment":443},{"nctId":"NCT05520177","phase":"PHASE3","title":"A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss","status":"COMPLETED","sponsor":"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.","startDate":"2022-12-27","conditions":"Branch Retinal Vein Occlusion","enrollment":351},{"nctId":"NCT05439629","phase":"PHASE3","title":"Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-07-07","conditions":"Neovascular (Wet) Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT06952452","phase":"PHASE3","title":"Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)","status":"RECRUITING","sponsor":"Parc de Salut Mar","startDate":"2022-11-18","conditions":"Wet Age-related Macular Degeneration","enrollment":630},{"nctId":"NCT03161652","phase":"PHASE2","title":"Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema","status":"RECRUITING","sponsor":"Carmen Clapp","startDate":"2017-05-24","conditions":"Diabetic Macular Edema, Diabetic Retinopathy","enrollment":120},{"nctId":"NCT06305416","phase":"PHASE3","title":"A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema","status":"RECRUITING","sponsor":"Incepta Pharmaceuticals Ltd","startDate":"2024-03-30","conditions":"Diabetic Macular Edema, Diabetic Retinopathy, Macular Edema","enrollment":70},{"nctId":"NCT06771271","phase":"PHASE1","title":"A Study to Investigate RO7200220 as Monotherapy and in Combination With Ranibizumab in Participants With Diabetic and Uveitic Macular Edema","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-07-22","conditions":"Diabetic Macular Edema, Uveitic Macular Edema","enrollment":85},{"nctId":"NCT05461339","phase":"PHASE3","title":"TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioDlink Biopharm Co., Ltd.","startDate":"2022-06-28","conditions":"Neovascular Age-related Macular Degeneration","enrollment":488},{"nctId":"NCT03927690","phase":"PHASE2","title":"Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-24","conditions":"Diabetic Macular Edema","enrollment":91},{"nctId":"NCT04075136","phase":"PHASE4","title":"Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2023-03-30","conditions":"Exudative Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT04667039","phase":"PHASE3","title":"Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®","status":"UNKNOWN","sponsor":"AO GENERIUM","startDate":"2022-03-20","conditions":"Age Related Macular Degeneration (ARMD)","enrollment":408},{"nctId":"NCT05480293","phase":"PHASE3","title":"This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD","status":"UNKNOWN","sponsor":"Sinocelltech Ltd.","startDate":"2023-02-14","conditions":"Wet Age-related Macular Degeneration","enrollment":446},{"nctId":"NCT01610557","phase":"PHASE2","title":"Ranibizumab and Bevacizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2012-05","conditions":"Diabetic Macular Edema","enrollment":56},{"nctId":"NCT02157077","phase":"PHASE3","title":"Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Centre Hospitalier Intercommunal Creteil","startDate":"2013-12","conditions":"Macular Degeneration, Wet Macular Degeneration, Retinal Degeneration","enrollment":90},{"nctId":"NCT05297292","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2021-05-07","conditions":"Wet Age-related Macular Degeneration","enrollment":433},{"nctId":"NCT01489189","phase":"PHASE3","title":"Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2012-03","conditions":"Proliferative Diabetic Retinopathy","enrollment":305},{"nctId":"NCT03150589","phase":"PHASE3","title":"A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2018-03-14","conditions":"Age-Related Macular Degeneration","enrollment":705},{"nctId":"NCT03038880","phase":"PHASE2","title":"Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-27","conditions":"Neovascularization, Choroidal, Macular Degeneration, Age-Related","enrollment":76},{"nctId":"NCT01934556","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2013-11","conditions":"Diabetic Macular Edema","enrollment":150},{"nctId":"NCT02484690","phase":"PHASE2","title":"A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-08-11","conditions":"Choroidal Neovascularization","enrollment":273},{"nctId":"NCT01627249","phase":"PHASE3","title":"Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2012-08","conditions":"Diabetic Macular Edema","enrollment":660},{"nctId":"NCT02462486","phase":"PHASE3","title":"Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-25","conditions":"Macular Degeneration","enrollment":949},{"nctId":"NCT02462928","phase":"PHASE3","title":"A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-06-25","conditions":"Macular Degeneration","enrollment":939},{"nctId":"NCT04387604","phase":"","title":"Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Centro Hospitalar do Porto","startDate":"2017-08-01","conditions":"Diabetic Macular Edema","enrollment":50},{"nctId":"NCT02976194","phase":"PHASE4","title":"Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy","status":"UNKNOWN","sponsor":"Pusan National University Hospital","startDate":"2016-11-22","conditions":"Exudative Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy","enrollment":28},{"nctId":"NCT00444600","phase":"PHASE3","title":"Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2007-03","conditions":"Diabetic Retinopathy, Diabetic Macular Edema","enrollment":691},{"nctId":"NCT01397409","phase":"PHASE2","title":"Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-09-01","conditions":"Age-related Macular Degeneration","enrollment":271},{"nctId":"NCT01945866","phase":"PHASE2","title":"Phase II Combination Steroid and Anti-VEGF for Persistent DME","status":"COMPLETED","sponsor":"Jaeb Center for Health Research","startDate":"2014-02","conditions":"Diabetic Macular Edema","enrollment":129},{"nctId":"NCT02530918","phase":"PHASE1","title":"Study of DS-7080a for the Treatment of Macular Degeneration","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2015-07","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":56},{"nctId":"NCT02002377","phase":"PHASE4","title":"Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections","status":"TERMINATED","sponsor":"Unity Health Toronto","startDate":"2014-04-17","conditions":"Age Related Macular Degeneration","enrollment":23},{"nctId":"NCT02321267","phase":"PHASE4","title":"Cohort Study of the Clinical Course of Macular Diseases in Kagawa","status":"UNKNOWN","sponsor":"Kagawa University","startDate":"2014-12","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT03452657","phase":"PHASE3","title":"Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-04","conditions":"Diabetic Retinopathy, Ranibizumab","enrollment":118},{"nctId":"NCT01134055","phase":"PHASE2","title":"Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-01","conditions":"Macular Degeneration","enrollment":510},{"nctId":"NCT01863199","phase":"PHASE4","title":"Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2013-05","conditions":"Neovascular Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT00593450","phase":"PHASE3","title":"Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-02","conditions":"Age Related Macular Degeneration","enrollment":1208},{"nctId":"NCT00456495","phase":"PHASE1","title":"Effect of Ranibizumab on Malignant Conjunctival Neoplasia","status":"COMPLETED","sponsor":"The New York Eye Cancer Center","startDate":"2007-03","conditions":"Conjunctival Neoplasms","enrollment":5},{"nctId":"NCT02727881","phase":"PHASE3","title":"Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD","status":"UNKNOWN","sponsor":"Ohr Pharmaceutical Inc.","startDate":"2016-04-12","conditions":"Age-related Macular Degeneration","enrollment":230},{"nctId":"NCT02181504","phase":"PHASE2","title":"A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-09","conditions":"Macular Degeneration","enrollment":25},{"nctId":"NCT01025232","phase":"PHASE1, PHASE2","title":"A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)","status":"TERMINATED","sponsor":"David M. Brown, M.D.","startDate":"2009-12","conditions":"Age Related Macular Degeneration, Choroidal Neovascular Membrane, Subfoveal Neovascular Age-Related Macular Degeneration","enrollment":88},{"nctId":"NCT00304954","phase":"PHASE2","title":"Infliximab, Sirolimus and Daclizumab to Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"2006-02","conditions":"Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":13},{"nctId":"NCT00942864","phase":"PHASE3","title":"Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)","status":"COMPLETED","sponsor":"Novartis Korea Ltd.","startDate":"2008-12","conditions":"Macular Edema, Retinal Vein Occlusion","enrollment":40},{"nctId":"NCT02081339","phase":"","title":"Cohort Study of the Clinical Course of Macular Diseases in Japanese","status":"UNKNOWN","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2014-03","conditions":"Macular Disease","enrollment":1000},{"nctId":"NCT02222207","phase":"PHASE2","title":"Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration","status":"TERMINATED","sponsor":"Bayer","startDate":"2014-10","conditions":"Macular Degeneration","enrollment":52},{"nctId":"NCT02181517","phase":"PHASE2","title":"A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Macular Degeneration","enrollment":25},{"nctId":"NCT01280929","phase":"PHASE2","title":"Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy","status":"COMPLETED","sponsor":"José Cunha-Vaz","startDate":"2010-09","conditions":"High Risk Proliferative Diabetic Retinopathy","enrollment":54},{"nctId":"NCT02186119","phase":"PHASE2","title":"A Study of Abicipar Pegol in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-07","conditions":"Macular Edema","enrollment":151},{"nctId":"NCT00557791","phase":"PHASE3","title":"Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)","status":"WITHDRAWN","sponsor":"OPKO Health, Inc.","startDate":"2009-11","conditions":"Age Related Macular Degeneration","enrollment":""},{"nctId":"NCT00637377","phase":"PHASE3","title":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-04","conditions":"Macular Degeneration","enrollment":1240},{"nctId":"NCT00499590","phase":"PHASE3","title":"Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD","status":"TERMINATED","sponsor":"OPKO Health, Inc.","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":338},{"nctId":"NCT02127684","phase":"PHASE2","title":"Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing","status":"WITHDRAWN","sponsor":"Maturi, Raj K., M.D., P.C.","startDate":"","conditions":"Persistent Diabetic Macular Edema","enrollment":""},{"nctId":"NCT00509795","phase":"PHASE3","title":"Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2007-08","conditions":"Macular Degeneration","enrollment":1217},{"nctId":"NCT00713518","phase":"PHASE2","title":"Phase II Open Label Multicenter Study For Age Related Macular Degeneration Comparing PF-04523655 Versus Lucentis In The Treatment Of Subjects With CNV (MONET Study).","status":"COMPLETED","sponsor":"Quark Pharmaceuticals","startDate":"2009-11","conditions":"Age Related Macular Degeneration","enrollment":152},{"nctId":"NCT01136252","phase":"PHASE2","title":"Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2010-05","conditions":"Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":5},{"nctId":"NCT01011374","phase":"PHASE1","title":"Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion","status":"UNKNOWN","sponsor":"Retina Associates of Cleveland, Inc","startDate":"2009-11","conditions":"Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":106,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lucentis every 4 weeks","genericName":"Lucentis every 4 weeks","companyName":"Retinal Consultants of Arizona","companyId":"retinal-consultants-of-arizona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lucentis (ranibizumab) blocks vascular endothelial growth factor A (VEGF-A) to inhibit abnormal blood vessel growth and reduce fluid leakage in the retina. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}